Online citations, reference lists, and bibliographies.
← Back to Search

HERMIONE: A Randomized Phase 2 Trial Of MM-302 Plus Trastuzumab Versus Chemotherapy Of Physician’s Choice Plus Trastuzumab In Patients With Previously Treated, Anthracycline-naïve, HER2-positive, Locally Advanced/metastatic Breast Cancer

K. Miller, J. Cortés, S. Hurvitz, I. Krop, D. Tripathy, S. Verma, K. Riahi, Joseph G. Reynolds, T. Wickham, I. Molnár, D. Yardley
Published 2016 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BackgroundHuman epidermal growth factor receptor 2 (HER2)-positive breast cancer is a particularly aggressive form of the disease, and ultimately progresses in patients with metastases on standard therapies. Anthracyclines, such as doxorubicin, are an effective treatment for HER2-positive breast cancer, particularly when administered in combination with trastuzumab – however, doxorubicin-related cardiotoxicity has limited its use. Many patients are therefore never treated with anthracyclines, even upon disease progression, despite the potential for benefit. MM-302 is a novel, HER2-targeted antibody–liposomal doxorubicin conjugate that specifically targets HER2­overexpressing cells. Preclinical and Phase 1 data suggest that MM-302, as a monotherapy or in combination with trastuzumab, could be effective for managing previously treated, anthracycline-naïve, HER2-positive breast cancer, without the cardiotoxicity observed with free doxorubicin formulations.Methods/DesignHERMIONE is an open-label, multicenter, randomized (1:1) Phase 2 trial of MM-302 plus trastuzumab versus chemotherapy of physician’s choice (gemcitabine, capecitabine, or vinorelbine) plus trastuzumab planned to enroll 250 anthracycline-naïve patients with locally advanced/metastatic HER2-positive breast cancer. Key inclusion criteria are: previous treatment with trastuzumab (with or without pertuzumab) in any setting; refractory or intolerant to pertuzumab (refractory to pertuzumab defined as progression in the locally advanced or metastatic setting, or disease recurrence during or within 12 months of completing pertuzumab-containing neoadjuvant and/or adjuvant therapy); and disease progression on, or intolerant to, ado-trastuzumab emtansine for locally advanced or metastatic disease. The trial is currently being conducted at sites in the USA, Canada, and Western Europe. Treatment will be administered in 21-day cycles, and will be continued until disease progression or unacceptable toxicity. The primary endpoint is independently assessed progression-free survival (PFS). Tumor response will be assessed every 6 weeks, and defined according to RECIST v1.1. Secondary endpoints include investigator-assessed PFS, overall survival (OS), OS rates at 6 months and 1 year, objective response rates, safety and tolerability, quality of life, and the pharmacokinetic profile of MM-302 plus trastuzumab.DiscussionThe HERMIONE study will evaluate the efficacy and safety of MM-302 plus trastuzumab in patients with refractory HER2-positive advanced/metastatic breast cancer for whom there are no standard of care therapies with a proven survival advantage.Trial RegistrationClinicaltrials.gov identifier: NCT02213744. Registration date: 06AUG2014.
This paper references
10.1200/JCO.2006.06.5391
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
S. Jones (2006)
10.1016/j.breast.2016.10.001
3rd ESO-ESMO international consensus guidelines for Advanced Breast Cancer (ABC 3).
F. Cardoso (2017)
10.1200/JCO.2008.20.5013
Pegylated liposomal doxorubicin plus docetaxel significantly improves time to progression without additive cardiotoxicity compared with docetaxel monotherapy in patients with advanced breast cancer previously treated with neoadjuvant-adjuvant anthracycline therapy: results from a randomized phase II
J. Sparano (2009)
10.1186/1471-2407-11-373
Single-agent pegylated liposomal doxorubicin (PLD) in the treatment of metastatic breast cancer: results of an Austrian observational trial
M. Fiegl (2011)
10.1158/0008-5472.SABCS13-P4-12-29
Abstract P4-12-29: Assessment of safety and activity in an expanded phase 1 study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced HER2-positive (HER2+) breast cancer
P. Munster (2013)
10.1056/NEJMoa1113216
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer.
J. Baselga (2012)
10.1007/s00280-008-0682-1
Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer
R. Bartsch (2008)
10.6004/JNCCN.2014.0058
Breast cancer version 3.2014.
W. Gradishar (2014)
10.1093/annonc/mdt182
Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA).
A. Schneeweiss (2013)
10.1016/j.ejca.2011.06.021
Trastuzumab beyond progression: overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer.
G. von Minckwitz (2011)
Gemzar (gemcitabine) -US prescribing information
Lilly (2014)
10.1159/000207504
Trastuzumab Combined with Pegylated Liposomal Doxorubicin in Patients with Metastatic Breast Cancer
C. Christodoulou (2009)
10.5858/arpa.2013-0953-SA
Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
A. Wolff (2014)
PEGylated -EU Summary of Product Characteristics
N V Janssen-Cilag International (2015)
Xeloda (capecitabine) – EU Summary of Product Characteristics
Hoffmann La Roche (2015)
Assessment of safety and activity in an expanded phase 1 study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced HER2positive (HER2+) breast cancer
P Munster (2013)
10.1634/theoncologist.2008-0230
The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine.
J. Ross (2009)
Xeloda (capecitabine) – EU Summary of Product Characteristics
La Hoffmann (2015)
10.1200/JCO.2013.31.15_SUPPL.610
Progression-free survival (PFS) as surrogate endpoint for overall survival (OS) in clinical trials of HER2-targeted agents in HER2-positive metastatic breast cancer (MBC): An individual patient data (IPD) analysis.
S. Michiels (2013)
10.1158/1538-7445.AM2015-CT234
Abstract CT234: A phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+ metastatic breast cancer
Patricia Lorusso (2015)
10.1200/JCO.2009.23.3734
Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer.
S. Johnston (2009)
10.1093/annonc/mdu385
ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)†
F. Cardoso (2014)
10.3978/j.issn.2305-5839.2014.08.13
Recent advances in the development of anti-HER2 antibodies and antibody-drug conjugates.
D. Wong (2014)
10.1056/NEJMoa1413513
Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer.
S. Swain (2015)
10.1200/JCO.2011.29.15_SUPPL.532
Efficacy of neoadjuvant therapy with trastuzumab concurrent with anthracycline- and nonanthracycline-based regimens for HER2-positive breast cancer.
S. Bayraktar (2011)
Ann Oncol
(2014)
Assessment of safety and activity in an expanded phase 1 study of MM-302, a HER2-targeted liposomal doxorubicin, in patients with advanced HER2- positive (HER2+) breast cancer
P Munster (2013)
A phase I study of MM-302, a HER2-targeted PEGylated liposomal doxorubicin, in patients with HER2+ metastatic breast cancer
P LoRusso (2015)
Xeloda (capecitabine) – US prescribing information
Hoffmann La Roche (2015)
10.1634/theoncologist.2010-0016
Underuse of Anthracyclines in Women with HER-2+ Advanced Breast Cancer
F. Montemurro (2010)
10.1136/esmoopen-2018-000327
Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: an individual patient data (IPD) analysis
M. Garassino (2018)
10.1200/JCO.2011.40.1273
Decline in the use of anthracyclines for breast cancer.
S. Giordano (2012)
Navelbine (vinorelbine) – EU Summary of Product Characteristics
Pierre Fabre (2011)
ESO-ESMO 2 nd international consensus guidelines for advanced breast cancer ( ABC 2 )
F. Cardoso (2014)
Recommendations for human epidermal growth factor receptor 2 testing in breast cancerCollege of American Pathologists clinical practice guideline update
Ac Wolff (2013)
10.3816/CBC.2009.n.029
Weekly gemcitabine and trastuzumab in the treatment of patients with HER2-overexpressing metastatic breast cancer.
D. Yardley (2009)
Breast cancer version 3
W J Gradishar (2014)
10.4048/jbc.2011.14.2.140
Phase II Study of Vinorelbine Plus Trastuzumab in HER2 Overexpressing Metastatic Breast Cancer Pretreated with Anthracyclines and Taxanes
Y. R. Lee (2011)
10.1016/j.taap.2012.04.008
HER2-targeted liposomal doxorubicin displays enhanced anti-tumorigenic effects without associated cardiotoxicity.
Joseph G. Reynolds (2012)
10.1016/S0140-6736(05)67134-6
Adjuvant trastuzumab for HER2-positive breast cancer
J. Spicer (2005)
10.1056/NEJMoa1209124
Trastuzumab emtansine for HER2-positive advanced breast cancer.
S. Verma (2012)
10.1158/1535-7163.MCT-13-0180
Impact of Tumor HER2/ERBB2 Expression Level on HER2-Targeted Liposomal Doxorubicin-Mediated Drug Delivery: Multiple Low-Affinity Interactions Lead to a Threshold Effect
B. Hendriks (2013)
10.1056/NEJM200103153441101
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
D. Slamon (2001)
10.1038/nrd3253
Microtubule-binding agents: a dynamic field of cancer therapeutics
C. Dumontet (2010)
Navelbine (vinorelbine) – US prescribing information
Pierre Fabre (2014)
10.1056/NEJMOA064320
Lapatinib plus capecitabine for HER2-positive advanced breast cancer.
C. Geyer (2006)
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxanerefractory advanced breast cancer
AM Keller (2004)
10.1093/annonc/mdt543
Phase III trial of nonpegylated liposomal doxorubicin in combination with trastuzumab and paclitaxel in HER2-positive metastatic breast cancer.
J. Baselga (2014)
10.1200/JCO.2005.03.8331
Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial.
S. Chia (2006)
10.1016/j.ygyno.2013.03.012
Continuing routine cardiac surveillance in long-term use of pegylated liposomal doxorubicin: is it necessary?
S. Gill (2013)
Pegylated liposomal doxorubicin ( doxil ) : Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg / m 2
iT. Safra (2005)
10.1093/ANNONC/MDH097
Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer.
M. O'Brien (2004)
10.1186/1471-2407-10-2
A multicentric observational trial of pegylated liposomal doxorubicin for metastatic breast cancer
J. Huober (2009)
10.1634/theoncologist.2009-0181
Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial
D. Cameron (2010)
Xeloda (capecitabine) – US prescribing information
La Hoffmann (2015)
10.1200/JCO.2010.30.8213
Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study.
M. Andersson (2011)
Gemzar (gemcitabine) -EU Summary of Product Characteristics
Lilly (2014)
10.1023/A:1008365716693
Pegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2.
T. Safra (2000)
10.1155/2013/456409
Liposomal Doxorubicin in the Treatment of Breast Cancer Patients: A Review
J. Lao (2013)
10.1016/S1470-2045(14)70178-0
Trastuzumab emtansine versus treatment of physician's choice for pretreated HER2-positive advanced breast cancer (TH3RESA): a randomised, open-label, phase 3 trial.
I. Krop (2014)
10.1126/SCIENCE.3798106
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D. Slamon (1987)
10.1200/JCO.2004.08.157
Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Alan M. Keller (2004)
10.1200/JCO.2008.19.6618
Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study.
G. von Minckwitz (2009)



This paper is referenced by
10.1016/j.jconrel.2018.02.040
Towards clinical translation of ligand‐functionalized liposomes in targeted cancer therapy: Challenges and opportunities
L. Belfiore (2018)
10.1016/j.jconrel.2018.02.015
Immunoliposomes in clinical oncology: State of the art and future perspectives
M. Merino (2018)
10.1080/17425247.2020.1814733
Peptides, proteins and nanotechnology: a promising synergy for breast cancer targeting and treatment
A. Sorolla (2020)
10.1016/j.colsurfb.2017.07.085
Immunoliposomes: A review on functionalization strategies and targets for drug delivery.
Josimar O. Eloy (2017)
10.1016/j.jconrel.2018.08.043
Cancer stem cells‐emanated therapy resistance: Implications for liposomal drug delivery systems
Hassan Dianat-Moghadam (2018)
10.1016/j.biopha.2019.108857
The promotion of nanoparticle delivery to two populations of gastric cancer stem cells by CD133 and CD44 antibodies.
H. Chen (2019)
10.1080/14737140.2018.1477596
Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects
M. Brandão (2018)
10.2217/nnm-2017-0043
Therapeutic targeting in nanomedicine: the future lies in recombinant antibodies.
G. Pietersz (2017)
saTB 1 sirna-encapsulated immunoliposomes conjugated with cD 44 antibodies target and eliminate gastric cancer-initiating cells
F. Yang (2018)
10.2217/fon-2018-0295
Targeted eradication of gastric cancer stem cells by CD44 targeting USP22 small interfering RNA-loaded nanoliposomes.
F. Yang (2019)
10.1080/13543784.2018.1520838
Targeted agents for HER2-positive breast cancer in older adults: current and future perspectives
E. Soto-Perez-de-Celis (2018)
10.1186/s12645-019-0055-y
Nanomedicine review: clinical developments in liposomal applications
Esteban Beltrán-Gracia (2019)
10.1007/978-3-319-94174-5_4
Moving Liposome Technology from the Bench to the Oncological Patient: Towards Performance-by-Design
A. F. Cruz (2018)
10.1080/14737140.2019.1660164
What therapies are on the horizon for HER2 positive breast cancer?
G. Viale (2019)
10.1007/s12609-017-0239-6
Targeting HER2/3 in Breast Cancer
A. Hepner (2017)
10.3389/fbioe.2019.00415
Overcoming Physiological Barriers to Nanoparticle Delivery—Are We There Yet?
O. S. Thomas (2019)
10.3389/fcvm.2020.00050
Human Pluripotent Stem Cell-Derived Cardiomyocytes for Assessment of Anticancer Drug-Induced Cardiotoxicity
V. Schwach (2020)
10.32768/abc.20196269-82
Nanomedicine , a new therapeutic strategy in breast cancer treatment
Amirali Taherian (2019)
10.1007/s13205-020-2144-3
Recent strategies towards the surface modification of liposomes: an innovative approach for different clinical applications
A. Khan (2020)
10.1007/s12609-017-0253-8
Systemic Therapy in the Setting of Central Nervous System (CNS) Metastases in Breast Cancer
Y. L. Chao (2017)
10.2147/OTT.S182437
SATB1 siRNA-encapsulated immunoliposomes conjugated with CD44 antibodies target and eliminate gastric cancer-initiating cells
F. Yang (2018)
10.1016/j.ddtec.2018.10.003
Antibody conjugated nanoparticles as a novel form of antibody drug conjugate chemotherapy.
M. Johnston (2018)
10.1016/j.xphs.2017.02.026
Recent Trends in Clinical Trials Related to Carrier-Based Drugs.
T. Tagami (2017)
10.21037/cco.2018.05.04
Advances in anti-HER2 therapy in metastatic breast cancer.
Minya Yao (2018)
10.1016/J.JDDST.2017.07.019
Recent advances in nanoparticle-mediated drug delivery
B. Kumar (2017)
10.1016/j.biopha.2018.11.118
Lipid-polymer nanoparticles with CD133 aptamers for targeted delivery of all-trans retinoic acid to osteosarcoma initiating cells.
Keke Gui (2019)
Development of Ligand-Directed Drug-Loaded Liposomes to Target Heterogeneous Tumour Cell Populations in Metastatic Breast Cancer
L. Belfiore (2019)
10.1208/s12248-017-0152-y
Nanotechnology as a Delivery Tool for Precision Cancer Therapies
B. Sharma (2017)
10.1016/j.jconrel.2019.11.016
A glance over doxorubicin based-nanotherapeutics: From proof-of-concept studies to solutions in the market.
M. Gonçalves (2019)
10.1016/j.addr.2020.05.012
Translational considerations in nanomedicine: The oncology perspective.
A. Gabizon (2020)
10.1134/S0026893317060097
Engineering Antibodies as Drugs: Principles and Practice
Alexey Alexandrovich Lugovskoy (2017)
Current Standards and New Treatment Insights in HER2-Driven Metastatic Breast Disease
R. Wang (2017)
See more
Semantic Scholar Logo Some data provided by SemanticScholar